sodium O-acetylsalicylate | 493-53-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sodium O-acetylsalicylate
• 英文别名: acetyl salicylic acid sodium salt；sodium acetylsalicylate；2-acetoxybenzoic acid sodium salt；aspirin sodium；sodium;2-acetyloxybenzoate
• CAS: 493-53-8
• 化学式: C₉H₇O₄*Na
• 分子量: 202.142
• InChiKey: JZLOKWGVGHYBKD-UHFFFAOYSA-M

物化性质

• 熔点：
  218 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -3.02
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 储存条件：
  库房应保持通风、低温和干燥，并需将物品与其他氧化剂、酸类以及食品化工添加剂分开存放。

制备方法与用途

类别：有毒物品
毒性分级：中毒
急性毒性：腹腔-大鼠 LD50: 1450 毫克/公斤；腹腔-小鼠 LD50: 500 毫克/公斤

可燃性危险特性：明火可燃，高热时能释放有毒的氧化钠气体

储运特性：应存放在通风、低温和干燥的库房中，并与氧化剂、酸类及食品化工添加剂分开存放

灭火剂：可用雾状水、泡沫、二氧化碳或砂土进行灭火

反应信息

• 作为反应物：
  描述：

  sodium O-acetylsalicylate 在 氯化亚砜 作用下， 反应 2.33h， 生成 邻乙酰水杨酰氯
  参考文献：
  名称：

  New 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, potassium channel activators. IV

  摘要：

  This paper reports the synthesis of a series of new 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, which have been tested for their activity as possible activators of potassium channels. In rat aortic rings, the 'opened' derivatives 1a-f, intermediates of synthesis, showed vasorelaxing properties, with appreciable values of potency. However, the most remarkable effects were recorded for the 2-hydroxybenzoylbenzotriazoles 3a-f, which showed full vasorelaxing efficacy and high potency values. The introduction of a 2-hydroxybenzyl substituent in the 1 position of the benzotriazole ring (compound 7) strongly decreased the activity, showing the importance of the electron-acceptor carbonyl function. The best compound, 3b, was further investigated, in order to evaluate the possible mechanism of action involved in the vasodilator activity. In the vascular model, different potassium channel blockers inhibited the effects of the compound, and an increase of the levels of membrane depolarisation induced a significant reduction of the recorded responses. Compound 3b was also tested in a model of isolated rat heart, retroperfused through the aorta and submitted to a global ischemia/reperfusion cycle. In such an experimental condition, 3b showed an interesting cardioprotective activity. All the above observations are in agreement with the hypothesis of a mechanism linked to the activation of potassium channels. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01146-6
• 作为产物：
  描述：

  阿司匹林 在 碳酸氢钠 作用下， 以 水 、 异丙醇 为溶剂， 以70 %的产率得到sodium O-acetylsalicylate
  参考文献：
  名称：

  具有潜在细胞毒性的新型二茂钛 (IV) 二羧酸盐：合成、结构、稳定性和电化学。

  摘要：

  寻找基于生物源金属的新抗癌药物，与铂类药物相比副作用更小，仍然是药物化学中的一项紧迫任务。二氯化钛是完全生物相容性钛的配位化合物，虽然在临床前试验中失败，但作为开发新型细胞毒性化合物的结构框架继续吸引研究人员的注意。在这项研究中，合成了一系列新的和文献中已知的二茂钛 (IV) 羧酸盐配合物，并通过一系列物理化学方法和 X 射线衍射分析（包括一个以前未知的结构基于全氟苯甲酸）。文献中已知的合成二茂钛衍生物的三种方法的综合比较（二氯化二茂钛的氯阴离子与羧酸的钠盐和银盐的亲核取代以及二甲基二茂钛与羧酸本身的反应）使得有可能优化这些方法以获得更高产量的单个目标化合物，概括这些技术的优缺点，并确定每种方法的底物框架。所有获得的二茂钛衍生物的氧化还原电势均通过循环伏安法测定。在这项工作中获得的配体结构、二茂钛 (IV) 的还原电位及其在氧化还原过程中的相对稳定性之间的关系，可用于设计和合成新型有效的细

  DOI：

  10.3390/ijms24043340

文献信息

• Bis(substituted benzoato) complexes of bis(η-cyclopentadienyl)titanium(IV). Synthesis and mass-, 1H-, 13C-NMR and IR-spectra
  作者：Y. Dang、H.J. Geise、R. Dommisse、E. Esmans、H.O. Desseyn

  DOI：10.1016/0022-328x(90)80063-6

  日期：1990.1

  The syntheses of 32 complexes of the type (η-C5H5)2Ti(OOCC6H4X)2 are reported together with their mass, 1H NMR, 13C NMR, mid- and far-IR spectra. The data are consistent with a model in which the TiOOC bond strength (weaker than that of TiCp and TiHal) is stabilized by electron-withdrawing substituents X on the phenyl rings. The electronic influence of X also extends into the cyclopentadienyl rings

  的类型的32种复合物的合成（η-C 5 H ^ 5）2的Ti（OOCC 6 H ^ 4 X）2与它们的质量，一起报告1 H NMR，13 C NMR，中期和远红外光谱。该数据与通过苯环上的吸电子取代基X稳定了TiOOC键强度（比TiCp和TiHal的强度弱）的模型一致。X的电子影响也延伸到环戊二烯基环中。
• Synthesis, characterization and behavior in water/DMSO solution of Ru(II) arene complexes with bioactive carboxylates
  作者：Lorenzo Biancalana、Guido Pampaloni、Stefano Zacchini、Fabio Marchetti

  DOI：10.1016/j.jorganchem.2018.05.020

  日期：2018.8

  sequential reaction of [RuCl(μ-Cl)(η6-p-cymene)]2 with sodium salicylate and PPh3 gave [Ru(κ2O,O′-salCO2)(PPh3)(η6-p-cymene)], 5, in 70% yield. The hydride complex [Ru2Cl2(μ-Cl)(μ-H)(η6-p-cymene)2], 6, was produced in 36% yield from [RuCl(μ-Cl)(η6-p-cymene)]2 and sodium formate. An optimization of the experimental work-up allowed to isolate [RuCl(μ-Cl)(η6-p-cymene)]2 with an improved yield respect to the

  将[RuCl（μ-Cl）的（η的反应6 - p -cymene）] 2与羧酸钠，在甲醇或乙腈溶液，得到复合物将[RuCl（κ 2 ö -RCO 2）（η 6 - p -cymene ）]（RCO 2  =丙戊酸盐，1；阿司匹林，2；双氯芬酸，3），收率79-96％。类似地，将[RuCl（κ 2 ö -dfCO 2）（η 6 -苯）]，4，在混合副产物将[RuCl（μ-Cl）的（η获得具有轻微的6 -苯）] 2和双氯芬酸钠/银。将[RuCl（μ-Cl）的（η的连续反应6 - p -cymene）] 2与水杨酸钠和PPH 3得到的[Ru（κ 2 ö，O' -salCO 2）（PPH 3）（η 6 - p -cymene）]，5，收率70％。的氢化物络合物的[Ru 2氯2（μ-Cl）的（μ-H）（η 6 - p -cymene）2 ]，6，在从产率将[RuCl（μ-Cl）的（η36％制备6 - p
• Process for the preparation of a pharmacologically active chemical combination
  申请人：Laboratori Alchemica S.r.l.

  公开号：US06369260B1

  公开（公告）日：2002-04-09

  Process for the preparation of a pharmacologically active chemical combination constituted by the association, through chemical bonds, of units equal to one another, having each an own pharmacological activity, and with the general formula (I): M—A—X—B—M, where M indicates said unit having an own pharmacological activity, X indicates a “bidentate” structure suitable to interconnect the M units, A and B indicate functional groups either equal to or different from one another which allow the interconnection between M and X.

  制备一种药物活性化学组合物的过程，该组合物通过化学键连接相等单元构成，每个单元均具有自身的药理活性，并具有通用公式(I)：M—A—X—B—M，其中M表示具有自身药理活性的单元，X表示适合于相互连接M单元的“双齿”结构，A和B表示相等或不同的功能团，它们允许M和X之间的相互连接。
• 13C NMR spectroscopic studies of the behaviors of carbonyl compounds in various solutions
  作者：Yoshikazu Hiraga、Saori Chaki、Satomi Niwayama

  DOI：10.1016/j.tetlet.2017.10.071

  日期：2017.12

  13C NMR spectroscopic studies were performed for carbonyl compounds having a hydroxyl group, a carboalkoxy group, an acetoxy group, or a carboxyl group in various solvents with different polarities for observation of their behaviors of 13C NMR chemical shifts of carbonyl carbons in solutions. It was found that the chemical shifts of the carbonyl carbons in 13C NMR have good correlation with the empirical

  在具有不同极性的各种溶剂中，对具有羟基，碳烷氧基，乙酰氧基或羧基的羰基化合物进行13 C NMR光谱研究，以观察其在溶液中的羰基碳的13 C NMR化学位移行为。发现在13 C NMR中羰基碳的化学位移与溶剂极性的经验参数E T N取决于结构，具有很好的相关性。分子间或分子内氢键和偶极-偶极相互作用似乎在这一观察中起关键作用。
• [EN] DERIVATIVES COMPRISING STEROLS AND/OR STANOLS AND SPECIFIC CLASSES OF ANTI-INFLAMMATORY AGENTS AND USE THEREOF IN TREATING OR PREVENTING CARDIOVASCULAR DISEASE<br/>[FR] DERIVES COMPRENANT DES STEROLS ET/OU DES STANOLS ET DES CLASSES SPECIFIQUES D'AGENTS ANTI-INFLAMMATOIRES, ET UTILISATION DESDITS DERIVES POUR LE TRAITEMENT OU LA PREVENTION DE MALADIES CARDIOVASCULAIRES
  申请人：FORBES MEDI TECH INC

  公开号：WO2004029068A1

  公开（公告）日：2004-04-08

  The present invention provides, in one aspect, novel derivatives comprising sterols and/or stanols and an NSAID selected from salicylic acids and arylalkanoic acids, including salts of these derivatives, and having one or more of the following formulae: a) R2-(CH2)n-CO-OR b) R2-R c) R2-CO-CO-OR d) formula (I), wherein R is a sterol or stanol moiety, R2 is derived from a salicylic acid or an arylalkanoic acid and n=1-5. Also provided are pharmaceutical compositions comprising one or more of these novel derivatives and methods of treating or preventing cardiovascular disease and its underlying conditions including, without limitation, atherosclerosis, hypercholesterolemia, hyperlipidemia, hypertension, thrombosis, coronary artery disease, and for treating and reducing inflammation including coronary plaque inflammation, bacterial-induced inflammation, viral induced inflammation and inflammation associated with acute pain and surgical procedures which comprises administering to an animal, particularly a human, a non-toxic and therapeutically effective amount of one or more of these compounds or a biologically acceptable salt thereof.

  本发明一方面提供了新颖的衍生物，包括甾醇和/或甾烷醇以及从水杨酸和芳烷酸中选择的非甾体抗炎药（NSAID），包括这些衍生物的盐，并具有以下一种或多种公式：a) R2-(CH2)n-CO-OR b) R2-R c) R2-CO-CO-OR d) 公式 (I)，其中R是甾醇或甾烷醇部分，R2来自水杨酸或芳烷酸，n=1-5。还提供了包含一种或多种这些新颖衍生物的药物组合物，以及治疗或预防心血管疾病及其基础条件的方法，包括但不限于动脉粥样硬化、高胆固醇血症、高脂血症、高血压、血栓形成、冠心病，以及治疗和减少炎症的方法，包括冠状动脉斑块炎症、细菌诱导的炎症、病毒诱导的炎症以及与急性疼痛和手术程序相关的炎症，该方法包括向动物，尤其是人类，投予一种或多种这些化合物或其生物学可接受的盐的非毒性和治疗有效量。